Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

March 9, 2018: By Joan McKenna

Imprimis Pharmaceuticals Inc. announced March 8 that its 2017 revenues totaled $26.77 million, a 34 percent increase over 2016 revenues of $19.94 million.

Fourth quarter revenues totaled $7.34 million, an increase of 27 percent over the 2016 total of $5.79 million.

The San Diego-based compounder said its average order at its 503B outsourcing facility in New Jersey was $1,400 in the fourth quarter.

Mark Baum, CEO of Imprimis, said Q4-2017 was the 15th consecutive quarter of double-digit or better year-over-year growth. The company’s customer network now exceeds 2 thousand prescribers, and it expects four new ophthalmic formulations to become available from its 503B facility during Q1-2018.

Imprimis attributed its annual revenue increase to a rise in sales and added ophthalmic formulations.

The company, which began generating revenues in 2014, has been attempting to disrupt the market with lower prices.

Imprimis said net losses for 2017 totaled $11.99 million. Its debt totaled $88.84 million at the end of 2017, and it expects to incur further losses as it continues to grow.

The company said it has raised more than $55 million through equity and debt financings since January 2015.

Addressing Supply Chain Vulnerabilities

On March 6, Imprimis announced that it has launched a new program to provide ophthalmologists and optometrists with custom compounded ophthalmic medications that are increasingly difficult to find, with products shipping within 24 to 48 hours.  Imprimis intends to make this program available in all 50 US states.

The move followed a Jan. 30 hearing by a US House subcommittee in which George Williams, MD, the AAO’s incoming president and a practicing retinal specialist in Michigan, testified that current FDA enforcement policies of state-regulated pharmacies is forcing practitioners to rely solely on outsourcing facilities, and sometimes only one facility, for office-use drugs, creating supply chain vulnerabilities.


Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023